Anaplastic Thyroid Cancer Clinical Trials

Find Anaplastic Thyroid Cancer Clinical Trials Near You

Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial

Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.

• Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).

• Measurable disease per RECIST 1.1

• ECOG performance status ≤ 2

• Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.

Locations
Other Locations
Netherlands
Radboudumc
RECRUITING
Nijmegen
Contact Information
Primary
R Netea-Maier, Prof. Dr.
romana.netea-maier@radboudumc.nl
+31243614599
Time Frame
Start Date: 2026-10-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 10
Treatments
Experimental: Personalized network-pharmacology-based combination therapy
Patients with advanced thyroid cancer undergo tumor molecular profiling using to identify personalized drug repurposing treatments. All drugs are administered at authorized therapeutic doses according to the summary of product characteristics. Treatment regimens vary between patients depending on the identified molecular profile.
Sponsors
Leads: Radboud University Medical Center
Collaborators: Horizon Europe, Maastricht University, EU Horizon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials